Aurelien Marabelle
MD, PhD
Clinical Director of Cancer Immunotherapy Program
👥Biography 个人简介
Aurelien Marabelle co-led KEYNOTE-158 and related pembrolizumab MSI-H basket studies that supported the first tumor-agnostic checkpoint inhibitor approval, establishing microsatellite instability-high and mismatch repair deficiency as pan-tumor predictive biomarkers. He also contributed to dostarlimab dMMR development. His work shaped tumor-agnostic IO biomarker strategy globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Aurelien Marabelle 的研究动态
Follow Aurelien Marabelle's research updates
留下邮箱，当我们发布与 Aurelien Marabelle（Gustave Roussy）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment